Home › Therapeutic areas › Hematology
Hematology (14 companies · 11 conditions)
Conditions
AL Amyloidosis 3 Rare Immune Thrombocytopenia 2 Rare Paroxysmal Nocturnal Hemoglobinuria 2 Rare Cold Agglutinin Disease 1 Rare Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy 1 Rare Hemophilia 1 Rare Iron Deficiency Anemia 1 Polycythemia Vera 1 Rare Sickle Cell Disease 1 Rare Systemic Mastocytosis 1 Rare Warm Autoimmune Hemolytic Anemia 1 Rare
Companies
| Ticker | Company | Therapeutic areas | In Hematology | Lead stage | Programs |
|---|---|---|---|---|---|
| AKBA | Akebia Therapeutics | HematologyOphthalmology+2 Rare | 1 | Approved | 10 |
| ANNX | Annexon | HematologyNeurology+2 Rare | 1 | Phase 3 | 6 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 1 | Approved | 12 |
| BEAM | Beam Therapeutics | HematologyMetabolic+1 Rare | 1 | Phase 2 | 6 |
| CLYM | Climb Bio | HematologyImmunology+1 Rare | 1 | Phase 2 | 7 |
| COGT | Cogent Biosciences | HematologyOncology Rare | 2 | NDA Submitted | 7 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 2 | NDA Submitted | 10 |
| FBIO | Fortress Biotech | DermatologyHematology+2 Rare | 1 | Approved | 12 |
| IMMX | Immix Biopharma | Hematology Rare | 1 | Phase 1 | 1 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | 1 | Phase 3 | 8 |
| OMER | Omeros | HematologyNeurology+2 Rare | 1 | Approved | 6 |
| QURE | uniQure | HematologyMetabolic+1 Rare | 1 | Approved | 4 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 1 | Approved | 29 |
| XNCR | Xencor | HematologyImmunology+4 Rare | 2 | Approved | 36 |
No companies match.